ENTRY       D08699            Mixture   Drug
NAME        Salmeterol xinafoate and fluticasone propionate;
            Adoair diskus (TN);
            Aerivio Spiromax (TN)
PRODUCT     ADVAIR (GlaxoSmithKline LLC)
            ADVAIR DISKUS (A-S Medication Solutions)
            ADVAIR HFA (GlaxoSmithKline LLC)
            AIRDUO DIGIHALER (Teva Respiratory)
            AIRDUO RESPICLICK (Teva Respiratory)
  GENERIC   FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions)
            FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions)
            FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions)
            FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions)
            FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack)
            FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack)
            FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack)
            FLUTICASONE PROPIONATE AND SALMETEROL (Hikma Pharmaceuticals USA)
            FLUTICASONE PROPIONATE AND SALMETEROL (Prasco Laboratories)
            FLUTICASONE PROPIONATE AND SALMETEROL (Preferred Pharmaceuticals)
            FLUTICASONE PROPIONATE AND SALMETEROL (Proficient Rx LP)
            FLUTICASONE PROPIONATE AND SALMETEROL (RPK Pharmaceuticals)
            FLUTICASONE PROPIONATE AND SALMETEROL (Teva Pharmaceuticals USA)
            FLUTICASONE PROPIONATE AND SALMETEROL (Teva Pharmaceuticals USA)
            FLUTICASONE PROPIONATE AND SALMETEROL HFA (Prasco Laboratories)
            WIXELA INHUB (Mylan Pharmaceuticals)
            WIXELA INHUB (REMEDYREPACK)
COMPONENT   Salmeterol xinafoate [DR:D00687], Fluticasone propionate [DR:D01708]
CLASS       Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2290
            ATC code: R01AD58 R03AK06
            Product: D08699<JP/US>
EFFICACY    Antiasthmatic
  DISEASE   Asthma [DS:H00079]
            Chronic obstructive pulmonary disease [DS:H01714]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R01 NASAL PREPARATIONS
               R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
                R01AD Corticosteroids
                 R01AD58 Fluticasone, combinations
                  D08699  Salmeterol xinafoate and fluticasone propionate &lt;JP/US&gt;
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03A ADRENERGICS, INHALANTS
                R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
                 R03AK06 Salmeterol and fluticasone
                  D08699  Salmeterol xinafoate and fluticasone propionate &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Bronchodilator Combinations
               Fluticasone Propionate/ Salmeterol
                D08699  Salmeterol xinafoate and fluticasone propionate
            Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              22  Respiratory organ agents
               229  Miscellaneous
                2290  Miscellaneous
                 D08699  Salmeterol xinafoate and fluticasone propionate
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D08699  Salmeterol xinafoate and fluticasone propionate
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D08699
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D08699
DBLINKS     PubChem: 96025382
///
